Non-surgery management after immunotherapy for GI cancers
Part of Cancer, Digestive system clinical trials.
This trial is for people with certain types of gastrointestinal cancers that have a genetic feature called MSI-H/dMMR or POLE mutation. It looks at whether, after immunotherapy, you can avoid surgery or have a less invasive procedure instead, such as watching and waiting, endoscopic removal, or limited surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a gastrointestinal cancer (like colorectal, stomach, or other) that is MSI-H/dMMR or has a POLE mutation.
- Your cancer was originally able to be removed with surgery (no spread to distant organs).
- You have already had, are currently having, or are about to start immunotherapy.
- You are in good physical condition (able to do daily activities without help).
- You do not have urgent need for surgery (like bleeding, blockage, or hole in the bowel).
- You have not had radiation to the pelvic area and can have an MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at whether people with certain gastrointestinal cancers who have had a very good response to targeted therapy or immunotherapy might be able to avoid surgery for now and instead be closely monitored. The goal is to see if this non-surgical approach is safe and effective.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
This trial tests a strategy to avoid surgery by using watchful waiting after initial treatment for early-stage rectal cancer. It may help patients keep their rectum and avoid a permanent colostomy.
This trial compares two approaches for patients with certain types of stomach or colon cancer that have specific genetic features (dMMR, MSI-H, or POLE mutations) and have responded well to immunotherapy: either closely monitoring without surgery, or proceeding with surgery. The goal is to see if some patients can safely avoid surgery while maintaining good outcomes.
This trial tests whether giving immunotherapy before surgery, with or without radiation, can help shrink locally advanced colorectal cancer that has a specific genetic marker (MSI-H or dMMR). It aims to improve outcomes for patients who have not yet had any treatment.
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
Hear when a new Gastrointestinal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.